SARS-CoV-2 infection
coronavirus disease 2019 (COVID-19)
myeloproliferative neoplasms
antithrombotic prophylaxis
antithrombotic therapy

How to Cite

Kostiukevych, O., Benkovska, L., Kravchenko, A., Chursina, T., & Mikhaliev , K. (2022). COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS. Clinical and Preventive Medicine, (4), 88-103.


Aim: to provide a literature review of the presently available data on the risk of thromboembolic events and current options for antithrombotic prophylaxis in patients with myeloproliferative neoplasms (MPN) patients with concomitant coronavirus disease 2019 (COVID-19).

Material and methods. The thematic scientific papers, published predominantly during the last decade (including the references regarding SARS-CoV-2 infection (COVID-19) of the last three years), constituted the study material. The research methodology involved bibliosemantic method and structural and logical analysis.

Results and discussion. MPN and SARS-CoV-2 infection (COVID-19) are both conditions with inherently enhanced susceptibility to thromboembolic events (venous and arterial). Along with the specific pathophysiological pathways, MPN and COVID-19, in case of their constellation, share overlapping pathomechanisms of hypercoagulability. As of today, the antithrombotic prophylaxis in MPN/COVID-19 patients (primary and secondary) is carried out according to the guidelines and algorithms, including those regarding general principles of the use of anticoagulants (oral or parenteral) and antiplatelet agents, and those specifically addressed to MPN or SARS-CoV-2 infection. These documents are constantly updating as the results of ongoing trials become available. Considering the relatively low prevalence of MPN, and the absence of specific guidelines, devoted to MPN in tandem with SARS-CoV-2 infection, the conduction of global registry studies is of crucial importance, aiming to provide a continuous and thorough collection and analysis of the data, related to the characteristics of this particular patients` population, pathological background and clinical features of thromboembolic complications, as well as short- and long-term outcomes.

Conclusion. The comprehensive study of basic, epidemiological and clinical data regarding various aspects of thrombosis/thromboembolism in case of MPN/COVID-19 constellation, is a multidisciplinary task, which should be performed with an ultimate goal to improve already implemented and develop novel approaches to antithrombotic management of such patients.


Cucinotta, D., & Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. Acta bio-medica : Atenei Parmensis, 91(1), 157–160.

Barbui, T., De Stefano, V., Alvarez-Larran, A., Iurlo, A., Masciulli, A., Carobbio, A., Ghirardi, A., Ferrari, A., Cancelli, V., Elli, E. M., Andrade-Campos, M. M., Kabat, M. G., Kiladjian, J. J., Palandri, F., Benevolo, G., Garcia-Gutierrez, V., Fox, M. L., Foncillas, M. A., Morcillo, C. M., Rumi, E., … Vannucchi, A. M. (2021). Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood cancer journal, 11(2), 21.

Kamaz, B., & Mullally, A. (2021). COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia, 35(1), 279–281.

Takasaki, K., Tsunenari, T., Mori, K., & Aochi, S. (2021). COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis. BMJ case reports, 14(11), e246700.

Falanga A. (2021). MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too. Hematology. American Society of Hematology. Education Program, 2021(1), 710–717.

Hultcrantz, M., Björkholm, M., Dickman, P. W., Landgren, O., Derolf, Å. R., Kristinsson, S. Y., & Andersson, T. (2018). Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study. Annals of internal medicine, 168(5), 317–325.

Rungjirajittranon, T., Owattanapanich, W., Ungprasert, P., Siritanaratkul, N., & Ruchutrakool, T. (2019). A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC cancer, 19(1), 184.

Falanga, A., & Marchetti, M. (2014). Thrombosis in myeloproliferative neoplasms. Seminars in thrombosis and hemostasis, 40(3), 348–358.

Guy, A., Gourdou-Latyszenok, V., Le Lay, N., Peghaire, C., Kilani, B., Dias, J. V., Duplaa, C., Renault, M. A., Denis, C., Villeval, J. L., Boulaftali, Y., Jandrot-Perrus, M., Couffinhal, T., & James, C. (2019). Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica, 104(1), 70–81.

Iba, T., Levy, J. H., Levi, M., & Thachil, J. (2020). Coagulopathy in COVID-19. Journal of thrombosis and haemostasis : JTH, 18(9), 2103–2109.

Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135(23), 2033–2040.

Joly, B. S., Siguret, V., & Veyradier, A. (2020). Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive care medicine, 46(8), 1603–1606.

Marchetti, M., Gomez-Rosas, P., Sanga, E., Gamba, S., Verzeroli, C., Russo, L., Restuccia, F., Schieppati, F., Bonanomi, E., Rizzi, M., Fagiuoli, S., D'Alessio, A., Lorini, L., & Falanga, A. (2021). Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction. TH open : companion journal to thrombosis and haemostasis, 5(3), e253–e263.

Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J. A., Blair, C., Weber, A., Barnes, B. J., Egeblad, M., Woods, R. J., Kanthi, Y., & Knight, J. S. (2020). Neutrophil extracellular traps in COVID-19. JCI insight, 5(11), e138999.

Leiva, O., Campia, U., Snyder, J., Barns, B. M., Rizzo, S., Khairani, C. D., Brunner, A., Al-Samkari, H., Leaf, R. K., Rosovsky, R., Goodarzi, K., Bornikova, L., Fathi, A., Goldhaber, S. Z., Hobbs, G., & Piazza, G. (2022). Patients with myeloproliferative neoplasms and COVID-19 have increased rates of arterial thrombosis. Research and practice in thrombosis and haemostasis, 6(5), e12752.

Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., Kucher, N., Studt, J. D., Sacco, C., Bertuzzi, A., Sandri, M. T., Barco, S., & Humanitas COVID-19 Task Force (2020). Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis research, 191, 9–14.

Cheruiyot, I., Kipkorir, V., Ngure, B., Misiani, M., Munguti, J., & Ogeng'o, J. (2021). Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review. Annals of vascular surgery, 70, 273–281.

Barbui, T., Finazzi, G., & Falanga, A. (2013). Myeloproliferative neoplasms and thrombosis. Blood, 122(13), 2176–2184.

Nopp, S., Moik, F., Jilma, B., Pabinger, I., & Ay, C. (2020). Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Research and practice in thrombosis and haemostasis, 4(7), 1178–1191.

Pasha, A. K., McBane, R. D., Chaudhary, R., Padrnos, L. J., Wysokinska, E., Pruthi, R., Ashrani, A., Daniels, P., Sridharan, M., Wysokinski, W. E., & Houghton, D. E. (2021). Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. Thrombosis research, 207, 150–157. Advance online publication.

Fahmy, O. H., Daas, F. M., Salunkhe, V., Petrey, J. L., Cosar, E. F., Ramirez, J., & Akca, O. (2021). Is Microthrombosis the Main Pathology in Coronavirus Disease 2019 Severity?-A Systematic Review of the Postmortem Pathologic Findings. Critical care explorations, 3(5), e0427.

Carsana, L., Sonzogni, A., Nasr, A., Rossi, R. S., Pellegrinelli, A., Zerbi, P., Rech, R., Colombo, R., Antinori, S., Corbellino, M., Galli, M., Catena, E., Tosoni, A., Gianatti, A., & Nebuloni, M. (2020). Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet. Infectious diseases, 20(10), 1135–1140.

Mueller-Peltzer, K., Krauss, T., Benndorf, M., Lang, C. N., Bamberg, F., Bode, C., Duerschmied, D., Staudacher, D. L., & Zotzmann, V. (2020). Pulmonary artery thrombi are co-located with opacifications in SARS-CoV2 induced ARDS. Respiratory medicine, 172, 106135.

Mandal, A., Kho, J., Ioannou, A., Van den Abbeele, K., & Missouris, C. G. (2021). Covid-19 and in situ pulmonary artery thrombosis. Respiratory medicine, 176, 106176.

Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., Braun, F., Lu, S., Pfefferle, S., Schröder, A. S., Edler, C., Gross, O., Glatzel, M., Wichmann, D., Wiech, T., Kluge, S., … Huber, T. B. (2020). Multiorgan and Renal Tropism of SARS-CoV-2. The New England journal of medicine, 383(6), 590–592.

Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020). Endothelial cell infection and endotheliitis in COVID-19. Lancet (London, England), 395(10234), 1417–1418.

Barbui, T., & De Stefano, V. (2021). Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic. Current hematologic malignancy reports, 16(5), 455–463.

Kahn, S. R., Lim, W., Dunn, A. S., Cushman, M., Dentali, F., Akl, E. A., Cook, D. J., Balekian, A. A., Klein, R. C., Le, H., Schulman, S., & Murad, M. H. (2012). Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e195S–e226S.

Schünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., Lansing, J., Balduzzi, S., Darzi, A., Morgano, G. P., Neumann, I., Nieuwlaat, R., Yepes-Nuñez, J. J., Zhang, Y., & Wiercioch, W. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood advances, 2(22), 3198–3225.

Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., Holley, A. B., Jimenez, D., Le Gal, G., Rali, P., & Wells, P. (2020). Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest, 158(3), 1143–1163.

Barnes, G. D., Burnett, A., Allen, A., Blumenstein, M., Clark, N. P., Cuker, A., Dager, W. E., Deitelzweig, S. B., Ellsworth, S., Garcia, D., Kaatz, S., & Minichiello, T. (2020). Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of thrombosis and thrombolysis, 50(1), 72–81.

Cuker, A., Tseng, E. K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., Davila, J., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Pai, M., Righini, M., Sanfilippo, K. M., Siegal, D., Skara, M., … Schünemann, H. J. (2021). American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood advances, 5(3), 872–888.

Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., Levi, M., Samama, C. M., Thachil, J., Giannis, D., Douketis, J. D., & Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis (2020). Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. Journal of thrombosis and haemostasis : JTH, 18(8), 1859–1865.

Marietta, M., Ageno, W., Artoni, A., De Candia, E., Gresele, P., Marchetti, M., Marcucci, R., & Tripodi, A. (2020). COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood transfusion = Trasfusione del sangue, 18(3), 167–169.

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., Gong, M. N., Carrier, M., Rosenson, R. S., Reynolds, H. R., Turgeon, A. F., Escobedo, J., Huang, D. T., Bradbury, C. A., Houston, B. L., Kornblith, L. Z., Kumar, A., … Zarychanski, R. (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. The New England journal of medicine, 385(9), 790–802.

Cuker, A., Tseng, E. K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., Davila, J., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D., Skara, M., Terrell, D. R., … Schünemann, H. J. (2021). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood advances, 5(20), 3951–3959.

Schulman, S., Sholzberg, M., Spyropoulos, A. C., Zarychanski, R., Resnick, H. E., Bradbury, C. A., Broxmeyer, L., Connors, J. M., Falanga, A., Iba, T., Kaatz, S., Levy, J. H., Middeldorp, S., Minichiello, T., Ramacciotti, E., Samama, C. M., Thachil, J., & International Society on Thrombosis and Haemostasis (2022). ISTH guidelines for antithrombotic treatment in COVID-19. Journal of thrombosis and haemostasis : JTH, 20(10), 2214–2225.

COVID-19 and myeloproliferative neoplasms: Frequently asked questions. COVID-19 and Myeloproliferative Neoplasms - (n.d.). Retrieved September 30, 2022, from

Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., McMahon, B., Mohan, S. R., Oh, S., Padron, E., Papadantonakis, N., Pancari, P., Podoltsev, N., Rampal, R., Ranheim, E., Reddy, V., … Sundar, H. (2017). NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN, 15(10), 1193–1207.

Finazzi, G., Vannucchi, A. M., & Barbui, T. (2018). Prefibrotic myelofibrosis: treatment algorithm 2018. Blood cancer journal, 8(11), 104.

U.S. Department of Health and Human Services. (n.d.). Information on COVID-19 treatment, prevention and research. National Institutes of Health. Retrieved September 30, 2022, from

Billett, H. H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L. R., Lo, Y., Rahman, S., Gonzalez-Lugo, J. D., Kushnir, M., Barouqa, M., Golestaneh, L., & Bellin, E. (2020). Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and haemostasis, 120(12), 1691–1699.

De Stefano, V., Finazzi, G., & Barbui, T. (2018). Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood cancer journal, 8(7), 65.

Kearon, C., Akl, E. A., Comerota, A. J., Prandoni, P., Bounameaux, H., Goldhaber, S. Z., Nelson, M. E., Wells, P. S., Gould, M. K., Dentali, F., Crowther, M., & Kahn, S. R. (2012). Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e419S–e496S.

Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., Stevens, S. M., Vintch, J., Wells, P., Woller, S. C., & Moores, L. (2016). Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 149(2), 315–352.

Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., Thurston, C., Vedantham, S., Verhamme, P., Witt, D. M., D Florez, I., Izcovich, A., Nieuwlaat, R., Ross, S., J Schünemann, H., Wiercioch, W., … Zhang, Y. (2020). American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood advances, 4(19), 4693–4738.

Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G. J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., Lake, E., Murin, S., Vintch, J., Wells, P. S., & Moores, L. K. (2021). Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest, 160(6), e545–e608.

Giannis, D., Allen, S. L., Tsang, J., Flint, S., Pinhasov, T., Williams, S., Tan, G., Thakur, R., Leung, C., Snyder, M., Bhatia, C., Garrett, D., Cotte, C., Isaacs, S., Gugerty, E., Davidson, A., Marder, G. S., Schnitzer, A., Goldberg, B., McGinn, T., … Spyropoulos, A. C. (2021). Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood, 137(20), 2838–2847.

Rashidi, F., Barco, S., Kamangar, F., Heresi, G. A., Emadi, A., Kaymaz, C., Jansa, P., Reis, A., Rashidi, A., Taghizadieh, A., Rezaeifar, P., Moghimi, M., Ghodrati, S., Mozafari, A., Foumani, A. A., Tahamtan, O., Rafiee, E., Abbaspour, Z., Khodadadi, K., Alamdari, G., … Ansarin, K. (2021). Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Thrombosis research, 198, 135–138.

Engelen, M. M., Vandenbriele, C., Balthazar, T., Claeys, E., Gunst, J., Guler, I., Jacquemin, M., Janssens, S., Lorent, N., Liesenborghs, L., Peerlinck, K., Pieters, G., Rex, S., Sinonquel, P., Van der Linden, L., Van Laer, C., Vos, R., Wauters, J., Wilmer, A., Verhamme, P., … Vanassche, T. (2021). Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization. Seminars in thrombosis and hemostasis, 47(4), 362–371.

Falanga, A., Marchetti, M., & Schieppati, F. (2021). Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. Hamostaseologie, 41(1), 48–57.

Barbui, T., De Stefano, V., Carobbio, A., Iurlo, A., Alvarez-Larran, A., Cuevas, B., Ferrer Marín, F., Vannucchi, A. M., Palandri, F., Harrison, C., Sibai, H., Griesshammer, M., Bonifacio, M., Elli, E. M., Trotti, C., Koschmieder, S., Carli, G., Benevolo, G., Ianotto, J. C., Goel, S., … Mascarenhas, J. (2021). Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia, 35(10), 2989–2993.

De Stefano, V., Za, T., Rossi, E., Vannucchi, A. M., Ruggeri, M., Elli, E., Micò, C., Tieghi, A., Cacciola, R. R., Santoro, C., Gerli, G., Vianelli, N., Guglielmelli, P., Pieri, L., Scognamiglio, F., Rodeghiero, F., Pogliani, E. M., Finazzi, G., Gugliotta, L., Marchioli, R., … GIMEMA CMD-Working Party (2008). Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 93(3), 372–380.

Al-Samkari, H., Karp Leaf, R. S., Dzik, W. H., Carlson, J., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., Leaf, D. E., Kuter, D. J., & Rosovsky, R. P. (2020). COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 136(4), 489–500.

Li, A., Kuderer, N. M., Hsu, C. Y., Shyr, Y., Warner, J. L., Shah, D. P., Kumar, V., Shah, S., Kulkarni, A. A., Fu, J., Gulati, S., Zon, R. L., Li, M., Desai, A., Egan, P. C., Bakouny, Z., Kc, D., Hwang, C., Akpan, I. J., McKay, R. R., … CCC19 consortium (2021). The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. Journal of thrombosis and haemostasis : JTH, 19(10), 2522–2532.

Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D'Sa, S., Eich, H. T., Foà, R., Ghia, P., da Silva, M. G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., … Passamonti, F. (2022). Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO open, 7(2), 100403.

Chen, M., & Anderson, L. D., Jr (2022). Preface of the Special Issue "COVID-19 Infection and Hematological Malignancies". Cancers, 14(18), 4497.

Langerbeins, P., & Hallek, M. (2022). COVID-19 in patients with hematologic malignancy. Blood, 140(3), 236–252.

Lucijanic, M., Krecak, I., Soric, E., Sedinic, M., Sabljic, A., Derek, L., Jaksic, O., & Kusec, R. (2021). Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism. Blood cancer journal, 11(11), 189.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.